# BMYBristol-Myers Squibb Company (BMY) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/BMY
## Company Profile
- Ticker: BMY
- Exchange: NYSE
- Sector: 肿瘤免疫治疗
- Location: Princeton, New Jersey
- Tags: Biopharma, Novel Therapies, Immunotherapy, Oncology, Cardio-Metabolic, Hematology
## Stock Data
- Close: 60.74 USD
- Market cap: 117582462402.26 USD
- Last updated: 2026-07-17
## Business Overview
Bristol Myers Squibb is a large-cap biopharmaceutical company with a portfolio spanning oncology, hematology, immunology, and cardiovascular disease. The market watches the stock for commercial durability, pipeline replacement, and the pace at which new assets offset lifecycle pressure.
## Why The Stock Is Moving

BMY is moving more like a steady commercial biopharma name than a stock in a sharp repricing phase. Its mature commercial base and diversified therapeutic exposure smooth volatility while the market waits for the next earnings or pipeline update.

## Geographic Base

Headquartered in Princeton, New Jersey and listed on NYSE, Bristol Myers Squibb is followed within the large-cap biopharmaceutical universe for its global commercial footprint and broad therapeutic exposure.

## Business Model

Bristol Myers Squibb combines commercial cash flow with pipeline renewal and business-development decisions. Earnings, launch execution, and data releases matter because they help the market judge whether the franchise can keep evolving after older products mature.

## Landscape Position

Compared with clinical-stage peers, Bristol Myers Squibb trades more like a mature commercial biopharma platform, where pipeline progress matters but balance-sheet support and portfolio durability also shape the story.

## Future Catalysts

- Over the next three months, focus stays on earnings, pipeline updates, conference commentary, and any regulatory milestones tied to ongoing programs.
- The next earnings call will likely be the first important checkpoint because it can update revenue trends, margin discipline, and the company's comments on patent lifecycle and capital allocation.
- Clinical data and conference updates also matter. Oncology and immunology readouts can quickly change the tone around the pipeline and the long-term replacement cycle.
- Regulatory and label milestones remain the main optionality layer. FDA decisions, supplemental filings, or label updates may shift the narrative around growth durability and portfolio expansion.

## Recent News
- 2026-07-20 10:59 EST — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-20 07:00 EST — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 09:00 EST — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc
- 2026-07-16 12:31 EST — [Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia](https://biopharmsignal.com/news/MRK/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-1b899588) — Source: Merck
- 2026-07-16 12:00 EST — [Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-resu-458d7635) — Source: Alnylam Pharmaceuticals, Inc.